• 1. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 2. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 3. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 4. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 5. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168

Recent Advances in the Study of 4H,5H,6H-cyclopentad1,3thiazole (CAS: 5661-10-9) in Chemical Biology and Pharmaceutical Research

The compound 4H,5H,6H-cyclopentad1,3thiazole (CAS: 5661-10-9) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This heterocyclic compound, characterized by a fused cyclopentadiene and thiazole ring system, exhibits remarkable chemical reactivity and biological activity, making it a promising candidate for drug development and biomedical applications.

Recent studies have focused on elucidating the synthetic pathways and pharmacological properties of 4H,5H,6H-cyclopentad1,3thiazole. A 2023 publication in the Journal of Medicinal Chemistry reported a novel, high-yield synthetic route for this compound, utilizing a cascade cyclization strategy that improves both efficiency and scalability. The study highlighted the compound's potential as a scaffold for designing inhibitors targeting key enzymes in inflammatory pathways, with preliminary in vitro assays showing promising activity against cyclooxygenase-2 (COX-2).

In parallel research, the compound's unique electronic properties have been investigated for applications in materials science. A team at MIT demonstrated in 2024 that derivatives of 4H,5H,6H-cyclopentad1,3thiazole can serve as efficient organic semiconductors in bioelectronic devices, owing to their excellent charge transport characteristics and stability in physiological environments. This dual applicability in both pharmaceutical and materials science domains underscores the compound's versatility.

Pharmacokinetic studies published in early 2024 have provided new insights into the metabolic fate of 4H,5H,6H-cyclopentad1,3thiazole derivatives. Using advanced LC-MS techniques, researchers identified three primary metabolic pathways, with hepatic glucuronidation being the dominant clearance mechanism. These findings are crucial for future drug design efforts, particularly in optimizing the compound's bioavailability and half-life.

The most groundbreaking development comes from a recent Nature Biotechnology paper (May 2024) demonstrating the compound's potential in targeted cancer therapy. By conjugating 4H,5H,6H-cyclopentad1,3thiazole derivatives with tumor-specific antibodies, researchers achieved selective delivery to cancer cells while minimizing off-target effects. In vivo studies showed significant tumor regression in multiple xenograft models with remarkably low systemic toxicity.

Despite these advances, challenges remain in the clinical translation of 4H,5H,6H-cyclopentad1,3thiazole-based therapeutics. Current research efforts are focused on addressing issues related to formulation stability and large-scale production. A recent industry-academia collaboration has made progress in developing nanocrystalline formulations that enhance the compound's solubility and shelf-life, as reported in the June 2024 issue of Advanced Drug Delivery Reviews.

Looking forward, the unique chemical and biological properties of 4H,5H,6H-cyclopentad1,3thiazole (5661-10-9) position it as a molecule of significant interest across multiple disciplines. Ongoing research is expected to further explore its potential in areas ranging from antimicrobial agents to neurodegenerative disease therapeutics, making it a compound worth watching in the coming years.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)